-
Bernstein Says Merck's Lung Cancer Drug Will Lead The Market Near-Term, But Long-Term Market Share Harder To Predict
Tuesday, August 9, 2016 - 11:49am | 385Read More...Tim Anderson, MD, a senior analyst at Bernstein, took a deep dive into Bristol-Myers Squibb Co (NYSE: BMY)'s announcement last Friday that its Checkmate-026 trial exploring the cancer fighting drug Opdivo in 1L lung failed. Related Link: Bristol-Myers Hit With A Trio Of Analyst Price Target...
